pre-IPO PHARMA

COMPANY OVERVIEW

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.


LOCATION

  • Boston, MA, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders

  • WEBSITE

    https://www.delixtherapeutics.com/


    CAREER WEBSITE

    https://www.delixtherapeutics.com/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 20, 2023

    Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001


    Jun 12, 2023

    Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer


    May 9, 2023

    Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001


    Feb 16, 2023

    Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity


    Feb 14, 2023

    Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability


    For More Press Releases


    Google Analytics Alternative